A comparison of two biomaterial carriers for osteogenic protein-1 (BMP-7) in an ovine critical defect model

Journal of Bone and Joint Surgery - Series B

Volumn 88, Issue 7, 2006, Pages 960-966

  Pluhar, G E ^a   Turner, A S ^b   Pierce, A R ^c   Toth, C A ^d   Wheeler, D L ^e  

^a UNIVERSITY OF MINNESOTA   (United States)

^b Department of Environmental and Radiological Health Sciences   (United States)

^c Stryker Orthopaedics   (United States)

^d Anika Therapeutics Inc   (United States)

^e CHARLES RIVER LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMATERIAL; CARBOXYMETHYLCELLULOSE; COLLAGEN; COLLAGEN TYPE 1; FENTANYL; PHENYLBUTAZONE; RECOMBINANT OSTEOGENIC PROTEIN 1;

ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOMECHANICS; BONE DEFECT; BONE REGENERATION; BONE REMODELING; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; HEALING; HISTOPATHOLOGY; IMPLANT; INFLAMMATION; INTERLOCKING NAIL; INTRAMEDULLARY NAIL; NONHUMAN; POSTOPERATIVE PAIN; PRIORITY JOURNAL; RADIODIAGNOSIS; RANDOMIZATION; SHEEP; SURGICAL APPROACH; SURGICAL TECHNIQUE; TIBIA; TREATMENT OUTCOME;

ANIMALS; BIOCOMPATIBLE MATERIALS; BIOMECHANICS; BONE DISEASES; BONE MORPHOGENETIC PROTEINS; BONE REGENERATION; CARBOXYMETHYLCELLULOSE; COLLAGEN TYPE I; DISEASE MODELS, ANIMAL; DRUG CARRIERS; DRUG IMPLANTS; FEMALE; RECOMBINANT PROTEINS; SHEEP; TIBIA; TRANSFORMING GROWTH FACTOR BETA;

EID: 33745937878     PISSN: 0301620X     EISSN: None     Source Type: Journal    
DOI: 10.1302/0301-620X.88B7.17056     Document Type: Article

References (43)

1. Younger EM, Chapman MW. Morbidity at bone graft donor sites. J Orthop Trauma 1989;3:192-5.
2. Bos GD, Goldberg VM, Powell AE. Heiple KG, Zika JM. The effect of histocompatibility matching on canine frozen bone allografts. J Bone Joint Surg [Am] 1983; 65-A:89-96.
3. Bos GD, Goldberg VM, Zika JM, Heiple KG Powell AE. Immune responses of rats to frozen bone allografts. J Bone Joint Surg [Am] 1983;65-A:239-46.
4. Goldberg VM, Stevenson S. Natural history of autografts and allografts. Clin Orthop 1987;225:7-16.
5. Buck BE, Resnick L, Shah SM, Malinin TI. Human immunodeficiency virus cultured from bone: implications for transplantation. Clin Orthop 1990;251:249-53.
6. Nemzek JA, Arnoczky SP, Swenson CL. Retroviral transmission in bone allotransplantation: the effects of tissue processing. Clin Orthop 1996;324:275-82.
7. Enneking WF, Campanacci DA. Retrieved human allografts: a clinicopathological study. J Bone Joint Surg [Am] 2001;83-A:971-86.
8. Enneking WF, Mindell ER. Observations on massive retrieved human allografts. J Bone Joint Surg [Am] 1991;73-A:1123-42.
9. Gouin F, Passuti N, Verriele V, Delecrin J, Bainvel JV. Histological features of large bone allografts. J Bone Joint Surg [Br] 1996;78-B:38-41.
10. Wheeler DL, Enneking WF. Allograft bone decreases in strength in vivo over time. Clin Orthop 2005;435:36-42.
11. Berrey BH Jr, Lord CF, Gebhardt MC, Mankin HJ. Fractures of allografts: frequency, treatment, and end-results. J Bone Joint Surg [Am] 1990;72-A:825-33.
12. Mankin HJ Doppelt S, Tomford W. Clinical experience with allograft transplantation: the first ten years. Clin Orthop 1983;174:69-86.
13. McDonald DJ, Maguire MH. Complications of large fragment allografts. In: Brown KLB, eds. Complications of limb salvage: prevention, management and outcome. 6th International Symposium, Montreal: ISOLS, 1991:25-8.
14. Thompson RC Jr, Pickvance EA, Garry D. Fractures in large-segment allograft. J Bone Joint Surg [Am] 1993;75-A:1663-73.
15. Woo BH, Fink BF, Page R, et al. Enhancement of bone growth by sustained delivery of recombinant human bone morphogenetic protein-2 in a polymeric matrix. Pharm Res 2001;18:1747-53.
16. Zehr RJ, Enneking WF, Heare T, Liang TS. Fractures in large structural allografts. In: Brown KLB, ed. Complications of limb salvage: prevention, management and outcome. 6th International Symposium, Montreal: ISOLS, 1991:3-8.
17. Chen X, Kidder LS, Lew WD. Osteogenic protein-1 induced bone formation in an infected segmental defect in the rat femur. J Orthop Res 2002;20:142-50.
18. Cook SD, Salkeld SL, Patron LP, Sargent MC, Rueger DC. Healing course of primate ulna segmental defects treated with osteogenic protein-1. J Invest Surg 2002; 15:69-79.
19. Cook SD. Preclinical and clinical evaluation of osteogenic protein-1 (BMP-7) in bony sites. Orthopedics 1999;22:669-71.
20. Cook SD, Salkeld SL, Brinker MR, Wolfe MW, Rueger DC. Use of an osteoinductive biomaterial (rhOP-1) in healing large segmental bone defects. J Orthop Trauma 1998;12:407-12.
21. Cullinane DM, Lietman SA, Inoue N, Deitz LW, Chao EYS. The effect of recombinant human osteogenic protein-1 (bone morphogenetic protein-7) impregnation on allografts in a canine intercalary bone defect. J Orthop Res 2002;20:1240-5.
22. Friedlaender GE, Perry CR, Cole JD, et al. Osteogenic protein-1 (bone morphongenetic protein-7) in the treatment of tibial nonunions. J Bone Joint Surg [Am] 2001; 83-A(Suppl 1)(Pt 2):151-8.
23. Geesink RG, Hoefnagels NH, Bulstra SK. Osteogenic activity of OP-1 bone morphogenetic protein (BMP-7) in a human fibular defect. J Bone Joint Surg [Br] 1999; 81-B:710-18.
24. Pecina M, Giltaij LR, Vukicevic S. Orthopaedic applications of osteogenic protein-1 (BMP-7). Int Orthop 2001;25:203-8.
25. Salkeld SL, Patron LP, Barrack RL, Cook SD. The effect of osteogenic bone protein-1 on the healing of segmental bone defects treated with autograft or allograft bone. J Bone Joint Surg [Am] 2001;83-A:803-16.
26. Reddi AH, Anderson WA. Collagenous bone matrix-induced endochondral ossification hemopoiesis. J Cell Biol 1976;69:557-72.
27. Aspenberg P, Lohmander LS. Fibroblast growth factor stimulates bone formation: bone induction studied in rats. Acta Orthop Scand 1989;60:473-6.
28. Santa-Comba A, Pereira A, Lemos R, et al. Evaluation of carboxymethylcellulose, hydroxypropylmethylcellulose, and aluminium hydroxide as potential carriers for rhBMP-2. J Biomed Mater Res 2001;55:396-400.
29. Scalia S, Giunchedi P, Pazzi P, Conte U. Enhancement of ursodeoxycholic acid bioavailability by cross-linked sodium carboxymethylcellulose. J Pharm Pharmacol 2000;52:383-8.
30. Ikechukwa Ugwoke M, Kaufmann G, Verbeke N, Kinget R. Intranasal bioavailability of apomorphine from carboxymethylcellulose-based drug delivery systems. Intl J Pharm 2000;202:125-31.
31. Duncan DB. Multiple range and multiple F tests. Biometrics 1955;11:1-42.
32. AQUALON® Cellulose Gum (Sodium Carboxymethylcellulose) summary of toxicological investigations. Hercules Incorporated, Bulletin T-123D, 1999.
33. Krukowski M, Snysders RV Jr, Eppley BL, Simmons DJ. Negatively charged resins stimulate bone formation in subperiosteal sites in rats: the effect of age. Clin Orthop 1994;298:266-71.
34. Tacchetti C, Tavella S, Dozin B, et al. Cell condensation in chondrogenic differentiation. Exp Cell Res 1992;200:26-33.
35. Key JA. The effect of a local calcium depot on osteogenesis and healing of fractures. J Bone Joint Surg 1934:16:176-84.
36. McBride J, Clyde M, Banks RE, Taylor D, Ryan J. Healing of segmental bone defects in goat tibia [abstract]. J Invest Surg 1993;6:369.
37. den Boer FC, Patka P, Bakker FC, et al. New segmental long bone defect model in sheep: quantitative analysis of healing with dual energy x-ray absoroptiometry. J Orthop Res 1999;17:654-60.
38. Wheeler DL, Jackinsky SW, Mohr KE, et al. Osteogenic protein-1 (OP-1/ BMP-7) enhanced cement as an OP-1 carrier for healing of tibial diaphyseal defects in an ovine model [abstract]. Trans Orthopaedic Research Society, 2004:467.
39. Wheeler DL, Jackinsky SW, Mohr KE, et al. Tricalcium phosphate putty as an OP-1 carrier for healing of tibial diaphyseal defects in an ovine model [abstract]. Trans Orthopaedic Research Society 2004:466.
40. Lanyon LE. Mechanical function and bone remodelling. In: Sumner-Smith G, ed. Bone in clinical orthopaedics. Philadelphia: Saunders, 1982:273-304.
41. Johnson EE, Urist MR. Human bone morphogenetic protein allografting for reconstruction of femoral nonunion. Clin Orthop 2000;371:61-74.
42. Johnson EE, Urist MR. One-stage lengthening of femoral nonunion augmented with human bone morphogenetic protein. Clin Orthop 1998;347:105-16.
43. Suh DY, Boden SD, Louis-Ugbo J, et al. Delivery of recombinant human bone morphogenetic protein-2 using a compression-resistant matrix in posterolateral spine fusion in the rabbit and in the non-human primate. Spine 2002;27:353-60.